The TMPRSS2-ERG fusion results in a high expression of the ERG gene and is believed to serve as a driving force behind prostate tumorigenesis.[68] Other groups have also identified such translocations in a high percentage of PCa patients.[69][70] Additional reports support the presence of ETS translocations in aggressive tumors and associates with high PCa-specific mortality.[69][71][72] The fusion events that involve ETS family members are likely to be important during early carcinogenesis events and continue to exist in metastatic and castration-resistant PCa. The gene discussed is TMPRSS2; the disease is posterior cortical atrophy.